Healthcare entity
NHS is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. regulation accounts for 3 of the 5 tracked stories, while 1 other category carries the remainder. They are better corroborated than the beat average, carrying 4.6 original sources each against 3.4 for the same window.
Last mentioned: Jun 15, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 60 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
NHS is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. regulation accounts for 3 of the 5 tracked stories, while 1 other category carries the remainder. They are better corroborated than the beat average, carrying 4.6 original sources each against 3.4 for the same window. The 7.2 average consequence score is above the beat benchmark of 5.9 in the same window. Against the same-window beat baseline of 23% negative, this entity's 20% share is less negative. That works out to roughly 0.3 stories per week across a 117-day span. This profile follows 5 Healthcare stories mentioning MHRA across the period from February 19, 2026 to June 15, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 736 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MHRA. Shared-story counts are live from our verified record — not editorial picks.
Committee Review
Expected date for health select committee to begin detailed scrutiny of the bill.
Expected Appeal Date
Final appraisal committee meeting to review new evidence and potential Managed Access Agreements.
National Campaign Launch
Bereaved family and patient advocates launch a coordinated media campaign imploring the NHS to reconsider.
Draft Law Unveiled
The Rare Cancers Law is formally introduced as a draft to Parliament.
Official Reporting
MHRA and GOV.UK release data confirming the surge in neurotech and AI testing activity.
NICE Initial Review
NICE issues a preliminary recommendation against routine funding based on cost-effectiveness.
Record Achievement
Total CINs for the year reach 137, a new historical high for the agency.
MHRA Approval
The drug receives safety and efficacy licensing for use in the UK market.
Policy Consultation
UK Government opens consultation on rare disease frameworks.
IDAP Expansion
The MHRA expands the Innovative Devices Access Pathway to include more AI-driven startups.
Baseline Growth
UK concludes 2024 with 104 clinical investigation notifications.
Advocacy Surge
Brain tumor charities increase lobbying efforts for legislative reform.
The MHRA approval of Novo Nordisk's oral semaglutide for obesity triggers a private prescribing boom, with pharmacies reporting 100,000 on waiting lists. The pill shows 87% of adherent patients in trials lost at least 5% body weight, with one in three losing 20%+. NHS discussions are under way, but no coverage timeline is set, leaving patients to navigate private costs.
The MHRA’s landmark approval of oral semaglutide introduces a needle-free GLP-1 option for obesity, backed by a 17% weight-loss result in adherent patients. Healthcare providers must now navigate private-only access and patient education around strict dosing protocols.
Source: investegate.co.uk · manilatimes.net
A bereaved family's national campaign has ignited a fierce debate over the NHS's refusal to fund a new treatment for aggressive cancer despite evidence of significant tumor shrinkage. The case underscores the growing tension between rapid pharmaceutical innovation and the UK's rigid cost-effectiveness appraisal frameworks.
The UK government is advancing a draft Rare Cancers Law designed to fast-track treatments and research for patients with incurable brain tumors. This legislative push aims to dismantle bureaucratic barriers that have historically hindered drug development and clinical trial access for rare oncological conditions.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) reported a record 137 clinical investigation notifications in 2025, a 32% increase over the previous year. This surge is driven by a strategic regulatory pivot toward AI-driven diagnostics and brain-computer interfaces, signaling the UK's intent to lead in high-risk medical innovation.
Source: Med-Tech Insights · GOV.UK
MHRA is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
